Date | Price Target | Rating | Analyst |
---|---|---|---|
4/29/2024 | Buy → Neutral | Guggenheim | |
1/24/2024 | $13.00 | Neutral | Goldman |
3/22/2023 | $20.00 → $6.00 | Buy → Neutral | Goldman |
12/1/2022 | $20.00 | Buy | Goldman |
12/29/2021 | $30.00 | Buy | Jefferies |
6/30/2021 | $41.00 → $21.00 | Buy | B. Riley Securities |
6/30/2021 | $53.00 → $31.00 | Market Outperform | JMP Securities |
6/30/2021 | $35.00 → $25.00 | Buy | HC Wainwright & Co. |
Guggenheim downgraded Altimmune from Buy to Neutral
Goldman initiated coverage of Altimmune with a rating of Neutral and set a new price target of $13.00
Goldman downgraded Altimmune from Buy to Neutral and set a new price target of $6.00 from $20.00 previously
DEF 14A - Altimmune, Inc. (0001326190) (Filer)
8-K - Altimmune, Inc. (0001326190) (Filer)
10-Q - Altimmune, Inc. (0001326190) (Filer)
GAITHERSBURG, Md., March 27, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Catherine Angell Sohn, Pharm.D. to its Board of Directors. "We are delighted to welcome Catherine to our Board of Directors," said Vipin K. Garg, Ph.D., President and Chief Executive Officer. "Her broad experience in the pharmaceutical industry including strategic product development, business development and commercialization will be invaluable to Altimmune as we pursue our mission to develop next generation peptide therapeutics for obesity and liver disease." Dr. Sohn added, "I am very honored and pleased to join the Altimmun
GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Raymond Jordt as Chief Business Officer, effective January 1, 2023. Mr. Jordt succeeds José Ochoa, who is leaving Altimmune to pursue other opportunities. Mr. Jordt is an accomplished executive with over 25 years of experience in the pharmaceutical industry. He joins Altimmune from Eli Lilly and Company, where he spent nearly two decades in various corporate and business development roles, most recently as Head of Transactions. During his tenure at Lilly, he led acquisitions, in/out-licensing, divestitures, collaborations, option
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 13, 2021 – ObsEva SA (NASDAQ:OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced the appointment of Will Brown as Chief Financial Officer and member of the company's Executive Committee, effective January 1, 2022. "We are thrilled to welcome Will, a highly accomplished biopharmaceutical executive with proven business development and financial acumen, to ObsEva's executive team," said Brian O'Callaghan, Chief Executive Officer of ObsEva. "This is an exciting time for ObsEva on the heels of the
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
SC 13G - Altimmune, Inc. (0001326190) (Subject)
https://nypost.com/2024/06/27/lifestyle/weight-loss-drug-pemvidutide-may-be-better-than-ozempic-trial/
Altimmune, Inc. (NASDAQ:ALT) shares are experiencing significant movement lower following the unexpected passing of Richard Eisenstadt, the company’s chief financial officer. What To Know: Eisenstadt’s sudden death has deeply saddened Altimmune, with CEO Vipin K. Garg highlighting his contributions and personal qualities that endeared him to colleagues. In response to Eisenstadt’s passing, Altimmune’s finance and accounting functions are temporarily being managed by the existing team while the company initiates a search for his replacement. This transition period aims to maintain stability amid the loss of a key executive. Altimmune is a clinical-stage biopharmaceutical firm specia
4 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
Recent presentations at major medical meetings provide further support for the differentiated profile of pemvidutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH) Enrollment progressing in Phase 2b IMPACT trial of pemvidutide in MASH with topline data expected in Q1 2025 Cash, cash equivalents and short-term investments of $164.9 million on June 30, 2024 Webcast to be held today, August 8, 2024, at 8:30 am ET GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2024, and provided a business update. "During the second
GAITHERSBURG, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on August 8 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will b
Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line results expected in Q1 2025 Cash, cash equivalents and short-term investments of $182.1 million at March 31, 2024 Webcast to be held today, May 9, 2024, at 8:30 am ET GAITHERSBURG, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024, and provided a business update. "As the obesity therapeutics space evolves, increasing attention is being placed on agents that are able to drive weight loss while addressing the qua
Lean Loss Ratio of only 21.9%, representing class-leading preservation of lean mass Maintenance of lean mass preservation in individuals over the age of 60, a population at risk for frailty-related falls and fractures Visceral adipose tissue (VAT), a risk factor for cardiovascular disease, reduced by 25.6% at Week 48 GAITHERSBURG, Md., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today presented data from its Phase 2, MRI-based body composition sub-study of pemvidutide in subjects with overweight and obesity at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain. Pemvidutide
GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that the data from its Phase 2, MRI-based body composition sub-study of pemvidutide in subjects with overweight and obesity will be presented at the 60th Annual Meeting of the European Association for the Study of Diabetes in Madrid, Spain. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). Details for the presentations are as follows: Title:Pemvidutide preserves lean body mass during weight loss in pati
Recent presentations at major medical meetings provide further support for the differentiated profile of pemvidutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH) Enrollment progressing in Phase 2b IMPACT trial of pemvidutide in MASH with topline data expected in Q1 2025 Cash, cash equivalents and short-term investments of $164.9 million on June 30, 2024 Webcast to be held today, August 8, 2024, at 8:30 am ET GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2024, and provided a business update. "During the second